Sharmela Kalmer

Sharmela is a trusted advisor to a number of emerging and established innovative technology and life sciences companies operating in a range of sectors, including biotech, medtech, foodtech and agritech. She has healthcare industry experience having worked in-house at Sanofi, Virgin Care Limited and Takeda Pharmaceuticals. Sharmela is also a member of the West London & GTAC (Gene Therapy Advisory Committee) NHS Research Ethics Committee and is involved in the ethical review of research involving cutting-edge technologies.

Clients in the technology and life sciences sectors have varied needs and face an ever-changing legal landscape. Sharmela's sector knowledge and insight has given her a solid understanding of the opportunities and issues faced by clients shaping the future and how to navigate these issues to access new market opportunities. She provides strategic and pragmatic advice across a company's lifecycle, from early development of technologies or medicines through to commercialisation of approved products or services. She has experience negotiating a variety of commercial and IP related contracts from licence, technology transfer and R&D agreements to manufacture and distribution agreements. Sharmela also provides advice on clinical trial-related agreements, interactions with regulatory authorities and compliance with ABPI Code of Conduct and industry best practices.